Statins moderate coronary stenoses but not coronary calcification: results from meta-analyses

Michael Y Henein1, Andrew Owen

  • 1Heart Centre and Department of Public Health and Clinical Medicine, Umea University, Sweden. Michael.henein@medicin.umu.se

Insights

Statins effectively moderate coronary artery stenoses by lowering LDL-C, but do not impact coronary artery calcification progression. This suggests different disease pathways, indicating statins are not effective for arterial calcification.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Statins are known to moderate coronary artery stenoses.
  • Evidence for statin effects on coronary artery calcification is lacking.
  • This study investigates statin impact on both conditions.

Purpose of the Study:

  • To perform meta-analyses on the effect of statin treatment on coronary artery stenoses and coronary artery calcification.
  • To compare the efficacy of statins in moderating stenosis versus calcification.

Main Methods:

  • Literature searches identified five controlled trials for coronary artery calcification (CAC) analysis and six for coronary stenoses analysis.
  • Trials compared high-dose statins against low-dose or placebo.
  • Meta-analyses were conducted on pooled trial data.

Main Results:

  • Statin treatment significantly reduced LDL-C by 1.0 mmol/L in CAC trials and 0.9 mmol/L in coronary stenoses trials.
  • No significant effect of statins was observed on the progression of coronary artery calcification.
  • A consistent moderation of coronary stenosis severity progression was found with statin use (p<0.0001).

Conclusions:

  • Statin therapy significantly moderates coronary stenoses, linked to LDL-C reduction.
  • Despite similar LDL-C reductions, statins showed no effect on coronary calcification progression.
  • Findings suggest distinct pathogenetic pathways for coronary stenoses and calcification, and limited efficacy of statins for arterial calcification.
Abstract

Related Concept Videos

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...